Tag: 1

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

AKVA group ASA (“AKVA”) today hosts a Capital Markets Day where it introduces a revenue target of NOK 5 billion and an EBIT target of 9% for 2027 and outlines its ambitions for continued profitable growth to NOK 7 billion in 2030.

On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.
Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting:

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

5. juunil 2025 võttis Arco Vara ASi aktsionäride korraline üldkoosolek vastu otsuse viia läbi suunatud aktsiaemissioon kindlatele investoritele eesmärgiga suurendada ettevõtte aktsiakapitali.
Arco Vara AS teatab, et aktsionäride poolt heaks kiidetud suunatud aktsiaemissioon on edukalt lõpetatud 11. juunil 2025 – juhatus on võtnud vastu otsuse märkimisperioodi lühendamiseks seoses välja lastud aktsiate ennetähtaegse märkimisega. Vastavalt vastu võetud üldkoosoleku otsusele:

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.